Psilocybin mushrooms

Traditional and historical use

Archaeological evidence of psilocybin mushroom use in Mesoamerica extends to at least 1000 BCE. Stone mushroom effigies from highland Guatemala, dated between roughly 1000 BCE and 900 CE, suggest organized ritual veneration of fungi — a practice sometimes termed mycolatry.^[15] Aztec sources refer to the mushrooms as teonanácatl ("flesh of the gods"), describing ceremonial consumption for healing, divination, and spiritual communion.

Western discovery

R. Gordon Wasson, an amateur mycologist, participated in a Mazatec velada led by curandera María Sabina in Oaxaca, Mexico in 1955. His account, published in Life magazine in May 1957, introduced the term "magic mushroom" — a phrase added by an editor without Wasson's consent — and catalyzed Western interest while ultimately disrupting Mazatec communities.^[16] Roger Heim provided the formal taxonomic description of Psilocybe mexicana in 1957, and Albert Hofmann at Sandoz Laboratories isolated psilocybin and psilocin the following year.^[3]

Research era and prohibition

Psychiatric research with psilocybin proceeded through the 1960s at Harvard and other institutions before being curtailed when psilocybin and psilocin were placed in Schedule I under the US Controlled Substances Act in 1970, and subsequently under the 1971 UN Convention on Psychotropic Substances.^[7] The physical mushroom was not explicitly named in the 1971 convention — a legal ambiguity later exploited in several jurisdictions.^[17]

Modern research revival

The Heffter Research Institute, founded in 1993, provided early infrastructure for renewed clinical work.^[18] Griffiths and colleagues published the pivotal 2006 study demonstrating that psilocybin could occasion mystical-type experiences with sustained personal meaning.^[8] Subsequent milestones include the COMPASS COMP360 Phase 2 trial for treatment-resistant depression,^[4] a single-dose MDD trial published in JAMA,^[5] Oregon's regulated therapeutic framework (operational 2023), Australia's authorization of therapeutic psilocybin (2023), and a US executive order in April 2026 directing fast-tracked psychedelic research review.^[7] No Phase 3 randomized controlled trial has been completed as of May 2026.

Taxonomy and classification

Psilocybe is a genus of small, spore-bearing fungi in the family Hymenogastraceae. Approximately 165 species are recognized, distributed across all continents except Antarctica.^[1] The most commonly encountered species in cultivation and commerce is Psilocybe cubensis, a pantropical fungus with numerous named cultivars (e.g., "Golden Teacher," "B+," "Penis Envy"). Psilocybe semilanceata (liberty cap) is the most widespread wild species in temperate Europe and North America.

Habitat and distribution

Psilocybe species occupy diverse ecological niches. P. cubensis fruits on bovine dung and enriched soils in tropical and subtropical regions. P. semilanceata grows in acidic grasslands, particularly sheep-grazed pastures in the British Isles, Scandinavia, and the Pacific Northwest. P. cyanescens (wavy cap) colonizes wood-chip mulch in urban and suburban settings. Wild populations of many species remain poorly surveyed outside North America and Western Europe.

Identification

Psilocybin-containing species share several macroscopic features: small to medium fruiting bodies, a hygrophanous cap (color shifts as moisture content changes), dark purple-brown spore prints, and — critically — blue bruising of damaged tissue, caused by oxidative polymerization of psilocin. Blue bruising is the most reliable field indicator of psilocybin content, though it is not unique to Psilocybe and may be absent in some low-potency species.

Misidentification is the most serious safety concern for wild foragers. Galerina marginata, a lethal amatoxin-containing species, co-occurs with P. cyanescens on wood-chip substrates and can appear similar to inexperienced collectors.^[14] Spore print color (Galerina: rusty brown; Psilocybe: dark purple-brown) is the primary distinguishing feature.

Harvesting and processing

Cultivated P. cubensis is typically harvested just before or as the veil separating cap from stem tears, then dried at low heat to preserve alkaloid content. Wild-harvested specimens require expert identification before consumption. Fruiting bodies are consumed dried, brewed as tea, or incorporated into edible preparations. Potency varies substantially: alkaloid content can differ up to 11-fold between individual specimens within a single species.^[9]

Dominant alkaloid: psilocybin and psilocin

psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) is the dominant alkaloid in Psilocybe mushrooms, functioning as a prodrug. After ingestion, alkaline phosphatases in the gut, liver, and blood cleave its phosphate group to yield psilocin (4-hydroxy-N,N-dimethyltryptamine) — the compound responsible for psychoactive effects. Psilocin acts as a partial agonist at serotonin 5-HT₂A receptors, the receptor interaction that drives the psychedelic experience.^[19] Psilocybin content in P. cubensis dried fruiting bodies typically ranges from approximately 0.14% to 1.86% by dry weight, though peer-reviewed HPLC data for individual cultivars remain sparse.^[20]

Minor alkaloids

Several minor tryptamine alkaloids co-occur with psilocybin in most Psilocybe species. Baeocystin (4-phosphoryloxy-N-methyltryptamine), the nor-methyl structural analog of psilocybin, is the most commonly reported minor constituent. Norbaeocystin (4-phosphoryloxy-tryptamine) is present at lower concentrations. Aeruginascin (trimethyl-4-phosphoryloxytryptamine) has been identified in some species, particularly P. cubensis strains anecdotally associated with experiential differences. No controlled human studies isolating the contributions of any minor alkaloid exist; their functional role in modulating the subjective experience is unresolved.

Variability

Alkaloid concentrations vary dramatically across species, cultivars, individual specimens, and even different regions of the same fruiting body. Within a single P. cubensis population, total psilocybin content can vary up to 11-fold.^[9] Growing conditions — substrate composition, temperature, humidity, and light exposure — influence alkaloid production. Named cultivar designations (e.g., "Penis Envy," "Albino A+") carry characteristic potency reputations among cultivators, but standardized analytical data are limited.^[20] This variability is the single largest unresolved challenge for consistent dosing with whole-mushroom preparations.

Pharmacokinetics summary

Psilocybin is converted to psilocin primarily by alkaline phosphatases before and during first-pass metabolism. Oral bioavailability of psilocin is approximately 52.7 ± 20%, with peak plasma concentrations reached at 1.8–4 hours and an half-life of 1.5–4 hours.^[21] Psilocin is metabolized principally via CYP2D6 and CYP3A4, with secondary metabolism by MAO-A.^[21] CYP2D6 poor metabolizers (approximately 5–10% of Caucasian populations) may experience prolonged psilocin exposure.^[21] Route-specific pharmacokinetics for tea preparations and other non-capsule oral forms have not been characterized in published studies.

Where it acts

Psilocin binds primarily to 5-HT₂A receptors on cortical pyramidal neurons in layers V and VI.^[19][22] PET imaging confirms that subjective psychedelic intensity correlates directly with 5-HT₂A receptor occupancy,^[2] and the selective antagonist ketanserin abolishes psilocybin's perceptual effects. Secondary activity at 5-HT₁A receptors may contribute an anxiolytic modulating tone.^[22] For detailed receptor binding data, see Psilocin.

What it changes

5-HT₂A activation triggers a cascade of glutamate release in cortical circuits. A 2024 Nature study demonstrated that a single 25 mg psilocybin dose produces massive desynchronization of brain connectivity — a broadband power reduction across posterior cortices and the default mode network (DMN), with connectivity changes exceeding three times those produced by methylphenidate.^[23] Psilocybin also promotes synaptogenesis and dendritic spine remodeling via BDNF upregulation through 5-HT₂A-mediated signaling.^[24] Persistent reductions in hippocampal-to-DMN connectivity lasting weeks after administration have been linked to therapeutic response in depression.^[23]

Two theoretical models dominate. The entropic brain hypothesis proposes that psilocybin elevates entropy in brain connectivity, pushing toward higher criticality with richer repertoires of functional states.^[25] The REBUS model integrates predictive processing: psilocybin relaxes rigid high-level prior beliefs, increasing sensitivity to bottom-up sensory input — a mechanism proposed to explain revision of entrenched depressive thought patterns.^[26]

Transient increases in blood pressure and heart rate occur during the acute psychedelic state. A case series of Psilocybe keralensis poisonings documented myocardial injury with cardiovascular complications — findings not replicated with P. cubensis or other commonly consumed species.^[29]

Contaminant and adulterant risk is preparation-dependent. Wild-harvested specimens carry misidentification risk with lethal species (see Botanical Overview) and potential pesticide or herbicide exposure from treated soils. Cultivated P. cubensis carries lower contamination risk under sterile conditions, though mold growth on inadequately dried material poses a mycotoxin concern.

Commercial edibles (chocolates, gummies) present the most significant adulteration risk: NPDS 2023–2024 data document unregulated products with unlisted ingredients and inconsistent formulations.^[30] Synthetic adulterants — particularly NBOMe-class compounds misrepresented as psilocybin — have been documented in the broader psychedelics market, primarily in pressed tablets and blotter. Whole dried mushrooms are less susceptible to synthetic adulteration than processed preparations.

Ehrlich reagent testing turns purple/violet in the presence of indole tryptamines including psilocybin and psilocin, providing a basic screening method. Ehrlich testing cannot confirm dose or distinguish between tryptamine compounds. No ISO/IEC-accredited laboratory testing framework exists for psilocybin mushroom products outside Australia's regulated therapeutic context.

In a nationally representative US adult sample, 8.9% of lifetime psychedelic users reported functional impairment lasting more than one day from their most challenging experience, and 2.6% sought medical or psychiatric assistance.^[10] Features include anxiety, panic, paranoia, thought loops, and ego dissolution experienced as frightening. These events generally resolve as drug effects wane.

Psilocybin is contraindicated in individuals with personal or family history of psychotic spectrum disorders. Clinical trials uniformly exclude these populations.^[17][5] Psilocybin may precipitate or exacerbate psychotic episodes in vulnerable individuals.^[17] safety citation needed

Hallucinogen persisting perception disorder (HPPD) is rare but documented. At least one case report describes HPPD persisting more than 8 months following combined psilocybin and cannabis use.^[31] Controlled data attribute flashback phenomena less strongly to psilocybin than to LSD.^[32]

Extended difficulties — including anxiety, existential struggle, social disconnection, and depersonalization — affect a subset of users. For approximately one-third of those reporting extended difficulties, problems persisted more than one year. Guided settings are associated with a narrower range of difficulties than unguided use.citation needed

Psilocybin produces no physical dependence or withdrawal.^[11][6] Psychological dependence liability is very low; no compulsive use patterns comparable to classical drugs of abuse have been documented.^[30] The rapid tolerance mechanism makes daily use pharmacologically self-limiting.

MAOIs — dangerous. Co-administration is associated with hypertensive urgency or emergency.^[12] MAO-A inhibition increases psilocin exposure while simultaneously elevating serotonin levels, creating both pharmacokinetic and pharmacodynamic amplification.

Tramadol — dangerous (pharmacological plausibility). Tramadol's serotonergic activity creates theoretical serotonin syndrome risk when combined with psilocybin. safety citation needed No peer-reviewed case reports of this specific combination have been identified.

Cannabis — unknown. One HPPD case followed combined psilocybin and cannabis use.^[31] Cannabis may amplify subjective intensity, but no controlled interaction studies exist.

SSRIs. Chronic SSRI use generally blunts psilocybin's effects through 5-HT₂A downregulation. A Phase 2 exploratory study of concurrent SSRI use found mild adverse events only and no serious events.^[33] The combination does not appear dangerous at standard SSRI doses but significantly reduces therapeutic efficacy.

CYP-mediated interactions. Psilocin is metabolized by CYP2D6 and CYP3A4.^[21] Strong inhibitors of these enzymes (e.g., fluoxetine, paroxetine, ketoconazole, ritonavir) could prolong psilocin exposure. CYP3A4 inducers (e.g., carbamazepine, rifampin) could reduce it. These interactions have not been systematically characterized in clinical studies.

Contraindications

Per-preparation dose tiers, timelines, and bioavailability data are in the Dose · by preparation card on this page.

Psilocybin and psilocin are listed in Schedule I of the 1971 UN Convention on Psychotropic Substances, though the physical mushroom was not explicitly named — a legal ambiguity exploited in several jurisdictions.^[17] The legal landscape is evolving rapidly: Australia authorized therapeutic use in 2023, Oregon and Colorado have established regulated access frameworks, and several European nations have initiated medical-access programmes. Possession remains a serious criminal offense in most jurisdictions worldwide. All status information should be independently verified against current legislation.^[7]

Treaty and analog considerations

The 1971 Convention schedules psilocybin and psilocin as chemical compounds but does not schedule the organisms that produce them. This distinction has practical legal consequences: in the Netherlands, psilocybin-containing truffles are sold legally because the prohibition specifies fruiting bodies rather than all psilocybin-containing fungi. Similar ambiguities exist in jurisdictions where legislation references the compound rather than the organism.^[17]